Clario, a provider of technologies and endpoint data solutions for clinical trials, recently announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpiroSphere with the wireless COR-12 Electrocardiogram (ECG) device. This technological advancement allows for the consecutive collection of spirometry and ECG data during a single site visit through Clario’s SpiroSphere platform, consolidating all data into a single, unified database. This streamlines the clinical trial process and eliminates the need for separate ECG devices or multiple databases for a study.
Originally launched in 2018, the SpiroSphere, a smart and lightweight pulmonary function testing (PFT) device, initially did not include ECG functionality. Now, the introduction of the SpiroSphere ECG features the wireless COR-12 ECG device. This advancement enables customers to run integrated respiratory and cardiac safety trials on a single device and single database, simplifying the clinical trial process.
“The launch of our FDA-cleared SpiroSphere wireless ECG device represents a significant step in improving clinical trial technology,” said Tom Stuckey, senior vice president, respiratory & precision motion at Clario. “This clearance and product launch emphasizes our commitment to optimizing data collection, efficiency, and consistency, further enhancing how we deliver respiratory trials with cardiac safety.”
Ellen Street, executive vice president, cardiac, respiratory & precision motion at Clario added, “Our SpiroSphere wireless ECG focuses on the site and patient experience while maintaining the high-quality data collection standards as our wired ECG model. With this wireless technology, site clinicians can now comfortably record both ECG and spirometry data in a single session on a single device, which can reduce the necessity for multiple devices, reduce burden, and accelerate trial timelines.”
This new product represents a technological advancement and offers a cost-effective solution for enhanced efficiency and patient experience, according to a news release.
For more information, visit Clario.com.
